Comparison of Bleeding Profiles of Sugammadex and Neostigmine in Orthotopic Liver Transplantation
H Liang, DO, R Chadha, MD, L White, J.R Renew, MD FASA FASE
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT :
Sugammadex is known to prolong prothrombin time (PT) and activated thromboplastin time (aPTT); however, there are still controversies about the relation between sugammadex and bleeding. Liver transplant recipients often present with abnormal coagulation profiles and other comorbidities before liver transplantation and have a higher risk of postoperative bleeding. We compare bleeding risk associated with sugammadex versus neostigmine during liver transplantation.
WHAT THIS STUDY ADDS :
Our retrospective study results demonstrate that sugammadex is not associated with increased postoperative bleeding events, had less PONV, did not affect the organ rejection rate, and did not affect hospital length of stay. We provide incremental evidence sugammadex can be considered as an alternative to antagonize neuromuscular blockade following orthotopic liver transplantation.